- Home
- AGEN vs SERA Comparison
AGEN vs SERA Comparison
Compare AGEN & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGEN | SERA |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.2M | 77.2M |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGEN | SERA |
|---|---|---|
| Price | $3.29 | $1.96 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 368.3K | 60.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $42,877,086.00 | $77,000.00 |
| Revenue This Year | $5.19 | $25.84 |
| Revenue Next Year | $68.25 | $715.79 |
| P/E Ratio | $8.95 | ★ N/A |
| Revenue Growth | ★ 89.95 | N/A |
| 52 Week Low | $1.38 | $1.37 |
| 52 Week High | $7.34 | $4.20 |
Technical Indicators
Market Signals| Indicator | AGEN | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 27.89 |
| Support Level | $2.90 | $1.37 |
| Resistance Level | $3.38 | $2.00 |
| Average True Range (ATR) | 0.18 | 0.23 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 62.51 | 14.02 |
Price Performance
Historical ComparisonAbout AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.